MRNA Net Margin
-141.43%TTM
Period ending:
MRNA FY Net Margin%
179.50%-964.43%
2016-12-312025-12-31
Source: Financial Modeling Prep (FMP). Annual fiscal periods. Dates are period ends; a fiscal year may differ from a calendar year.
MRNA net margin history
Net income as a percentage of revenue. The available annual fiscal periods series contains 10 observations from Dec 31, 2016 to Dec 31, 2025.
| Period ending | Net Margin |
|---|---|
| -145.1646% | |
| -111.316% | |
| -68.8376% | |
| 44.302% | |
| 68.7979% | |
| -92.9884% | |
| -853.7278% | |
| -284.8447% | |
| -124.3367% | |
| -199.464% |
Compare net margin
Other companies in Healthcare. Each page shows its own reporting periods and currency.
- Lilly (Eli) (LLY) net margin
- Johnson & Johnson (JNJ) net margin
- AbbVie (ABBV) net margin
- UnitedHealth Group (UNH) net margin
- Merck & Co. (MRK) net margin
- Thermo Fisher Scientific (TMO) net margin
- Amgen (AMGN) net margin
- Gilead Sciences (GILD) net margin
Compare all covered stocks by net margin →
All MRNA financial metrics · MRNA stock overview · How to interpret financial metrics
